File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma

TitleA novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma
Authors
KeywordsAnti-tumor
Cocktail gene therapy
Hepatocellular carcinoma
HGFK1
Issue Date2008
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet
Citation
Cancer Letters, 2008, v. 272 n. 2, p. 268-276 How to Cite?
AbstractHepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, yet effective therapeutic options for advanced HCC are limited. Kringle 1 domain of HGF (HGFK1) has been demonstrated as a potent anti-tumor molecule and p53 is a well established tumor suppressor. Recently we developed AAV transducing HGFK1 (AAV-HGFK1) as a gene therapy for HCC. Here we investigated the possibility of enhancing the effect of AAV-HGFK1 by combining it with Adv transducing p53 (Adv-p53). In vitro expression experiments suggested a small amount of Adv-p53 could increase the expression of AAV transgenes. AAV-HGFK1 + Adv-p53 cocktail strongly inhibited the proliferation of microvascular endothelial cell (MEC) and two HCC cell lines, Hepa1-6 and McA-RH7777. In two orthotopic mice and rat HCC models the cocktail gene therapy also significantly reduced the tumor burdens and prolonged the survival time by inhibiting tumor angiogenesis and inducing tumor cell death. Significantly, tumor metastasis was completely prevented. AAV-HGFK1 + Adv-p53 viral cocktail may be a promising cancer therapy for the treatment of HCC. © 2008 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/58366
ISSN
2023 Impact Factor: 9.1
2023 SCImago Journal Rankings: 2.595
ISI Accession Number ID
Funding AgencyGrant Number
ITC of the Hong Kong Special Administrative Region, ChinaITS/084/03
RGCHKU7705/07M
Funding Information:

This study was supported by grants from the ITC of the Hong Kong Special Administrative Region, China (ITS/084/03) and RGC (HKU7705/07M).

References
Grants

 

DC FieldValueLanguage
dc.contributor.authorShen, Zen_HK
dc.contributor.authorWong, OGWen_HK
dc.contributor.authorYao, RYen_HK
dc.contributor.authorLiang, Jen_HK
dc.contributor.authorKung, HFen_HK
dc.contributor.authorLin, MCMen_HK
dc.date.accessioned2010-05-31T03:29:03Z-
dc.date.available2010-05-31T03:29:03Z-
dc.date.issued2008en_HK
dc.identifier.citationCancer Letters, 2008, v. 272 n. 2, p. 268-276en_HK
dc.identifier.issn0304-3835en_HK
dc.identifier.urihttp://hdl.handle.net/10722/58366-
dc.description.abstractHepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, yet effective therapeutic options for advanced HCC are limited. Kringle 1 domain of HGF (HGFK1) has been demonstrated as a potent anti-tumor molecule and p53 is a well established tumor suppressor. Recently we developed AAV transducing HGFK1 (AAV-HGFK1) as a gene therapy for HCC. Here we investigated the possibility of enhancing the effect of AAV-HGFK1 by combining it with Adv transducing p53 (Adv-p53). In vitro expression experiments suggested a small amount of Adv-p53 could increase the expression of AAV transgenes. AAV-HGFK1 + Adv-p53 cocktail strongly inhibited the proliferation of microvascular endothelial cell (MEC) and two HCC cell lines, Hepa1-6 and McA-RH7777. In two orthotopic mice and rat HCC models the cocktail gene therapy also significantly reduced the tumor burdens and prolonged the survival time by inhibiting tumor angiogenesis and inducing tumor cell death. Significantly, tumor metastasis was completely prevented. AAV-HGFK1 + Adv-p53 viral cocktail may be a promising cancer therapy for the treatment of HCC. © 2008 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canleten_HK
dc.relation.ispartofCancer Lettersen_HK
dc.rightsCancer Letters. Copyright © Elsevier Ireland Ltd.en_HK
dc.subjectAnti-tumoren_HK
dc.subjectCocktail gene therapyen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectHGFK1en_HK
dc.titleA novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0304-3835&volume=272&issue=2&spage=268&epage=276&date=2008&atitle=A+Novel+and+Effective+Hepatocyte+Growth+Factor+Kringle+1+Domain+and+p53+Cocktail+Viral+Gene+Therapy+for+the+Treatment+of+Hepatocellular+Carcinomaen_HK
dc.identifier.emailLin, MCM:mcllin@hkucc.hku.hken_HK
dc.identifier.authorityLin, MCM=rp00746en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.canlet.2008.03.064en_HK
dc.identifier.pmid18722051en_HK
dc.identifier.scopuseid_2-s2.0-55949123311en_HK
dc.identifier.hkuros149878en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-55949123311&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume272en_HK
dc.identifier.issue2en_HK
dc.identifier.spage268en_HK
dc.identifier.epage276en_HK
dc.identifier.isiWOS:000261755900011-
dc.publisher.placeIrelanden_HK
dc.relation.projectDevelopment of Novel AAV based anti-angiogenesis gene therapy for the treatment of liver cancer-
dc.identifier.scopusauthoridShen, Z=35759640300en_HK
dc.identifier.scopusauthoridWong, OGW=7004813981en_HK
dc.identifier.scopusauthoridYao, RY=7102766169en_HK
dc.identifier.scopusauthoridLiang, J=36087584100en_HK
dc.identifier.scopusauthoridKung, HF=7402514190en_HK
dc.identifier.scopusauthoridLin, MCM=7404816359en_HK
dc.identifier.issnl0304-3835-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats